# US 2003/0077327 A1 · Highly compressible ethylcellulose for tableting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077327 A1
- Document ID: US20030077327A1
- Status: Published application
- Kind: A1
- Application number: 09/977,785
- Filed: 2001-10-15
- Published: 2003-04-24
- Earliest claimed: 2001-10-15
- Assignees: Hercules Incorporated
- Inventors: Thomas Durig; Ronald Haywood Hall; Richard A. Salzstein
- Web page: https://patentgrep.com/patent/US20030077327A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/26: Androgens
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/06: Antiasthmatics
- A61P 11/10: Expectorants
- A61P 11/12: Mucolytics
- A61P 11/14: Antitussive agents
- A61P 13/06: Anti-spasmodics
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 23/02: Local anaesthetics
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical dosage form composition is composed of an ethylcellulose that has an ethoxyl range lower limit of 49.6%, an a viscosity of less than 53 cps and at least one active pharmaceutical ingredient. This dosage form is highly compressible and compactible forming harder tables or pellets with better release retardation than comparable prior art tablets.

## Claims

### Claim 1

A pharmaceutical dosage form composition comprising
a) ethylcellulose that has an ethoxyl range lower limit of 49.6% and a viscosity of less than 53 cps as measured on a Hercules Horizontal Capillary Viscometer at a temperature of 25° C. in a 5% solution, and
b) at least one active pharmaceutical ingredient.

### Claim 2 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the ethylcellulose has a glass transition temperature (Tg) of less than 130° C.

### Claim 3 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the ethylcellulose has a glass transition temperature (Tg) of less than 128° C.

### Claim 4 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the ethylcellulose has an average particle size of greater than 50 micrometers.

### Claim 5 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the pharmaceutical dosage form has a compression strength greater than the analogous dosage form comprising ethylcellulose of similar form but has an ethoxyl range less than 49.6%.

### Claim 6 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the pharmaceutical dosage form has a compression strength greater than the analogous dosage form comprising ethylcellulose of similar form but has a viscosity of greater than 50 cps.

### Claim 7 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the dosage form is a tablet or pellet.

### Claim 8 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the dosage form is a multiparticulate.

### Claim 9 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein ethylcellulose is in a barrier coating.

### Claim 10 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the lower limit of the ethoxyl range is 49.8%.

### Claim 11 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the lower limit of the ethoxyl range is 50.0%.

### Claim 12 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the upper limit of the ethoxyl range is 54.88%.

### Claim 13 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the upper limit of the ethoxyl range is 53.0%.

### Claim 14 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the upper limit of the ethoxyl range is 52.0%.

### Claim 15 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the upper limit of the ethylcellulose viscosity is less than 25 cps.

### Claim 16 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the upper limit of the ethylcellulose viscosity is less than 17 cps.

### Claim 17 (depends on 1)

The pharmaceutical dosage form composition of claim 1, wherein the lower limit of the ethylcellulose viscosity is about 3 cps.

### Claim 18 (depends on 1)

The pharmaceutical dosage form composition to claim 1 wherein the active pharmaceutical ingredient is selected from the group consisting of antacids, anti-inflammatory substances, anti-infectives, psychotropics, antimanics, stimulants, antihistamines, laxatives, decongestants, nutritional supplements, gastrointestinal sedatives, antidiarrheal preparations, antianginal drugs, antiarrhythmics, antihypertensive drugs, vasoconstrictors and migraine treatments, anticoagulants and anti-thrombotic drugs, analgesics, anti-pyretics, hypnotics, sedatives, antiemetics, anti-nauseants, anticonvulsants, neuromuscular drugs, hyper- and hypoglycemic agents, thyroid and antithyroid preparations, diuretics, antispasmodics, uterine relaxants, mineral and nutritional additives, anti-obesity drugs, anabolic drugs, erythropoietic drugs, antiasthmatics, expectorants, cough suppressants, mucolytics, antiuricemic drugs, topical analgesics, local anesthetics, polypeptide drugs, anti-HIV drugs, chemotherapeutic and anti-neoplastic drugs and mixtures thereof.

### Claim 19 (depends on 9)

The pharmaceutical dosage form composition of claim 9 wherein the active pharmaceutical ingredients are selected from the group consisting of phenylpropanolamine hydrochloride, aluminum hydroxide, prednisolone, dexamethasone, aspirin, acetaminophen, ibuprofen, isosorbide dinitrate, nicotinic acid, tetracycline, ampicillin, dexbrompheniramine, chlorpheniramine, albuterol, pseudoephedrine, loratadine, theophylline, ascorbic acid, tocopherol, pyridoxine, methoclopramide, magnesium hydroxide, verapamil, procainamide hydrochloride, propranolol, captopril, ergotamine, flurazepam, diazepam, lithium carbonate, insulin, furosemide, hydrochlorothiazide, guaiphenesin, dextromethorphan, benzocaine, and mixtures thereof.

### Claim 20 (depends on 1)

The pharmaceutical dosage form of claim 1, wherein the ethylcellulose has high flowability as measured by an angle of repose of less than 35° C., or an angle of slide of less than 45° C.
